Bushen Tongzhi Formula
Phase 3Small molecule
Bushen Tongzhi Formula is one of 17 small molecule programs targeting Ovarian Reserve. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Ovarian Reserve
#DrugCompanyPhaseTrials
1Myoinositol
SSohag University
Phase 3
Bushen Tongzhi Formula
PPeking Union Medical College Hospital
Phase 3
Co-Enzyme Q10
TTanta University
Phase 3
Thalomid
Bristol-Myers SquibbPreclinical
Remicade
Johnson & JohnsonPreclinical
Trexall
Jazz PharmaceuticalsPreclinical
Danocrine
SanofiPreclinical
Zoladex
TTerSera Therapeutics LLC
Preclinical
Growth Hormone
PfizerPreclinical
Recombinant LH
UUniversity of Colorado, Denver
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bushen Tongzhi Formula. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details